1Reith JD, Goldblum JR, Lyles RH, et al. Extragastrointestinal (soft tissue) stromal tumors: an analysis of 48 cases with emphasis on histologic predictors of outcome.Mod Pathol,2000,13:577-585.
2Zighelboim I, Henao G, Kunda A, et al. Gastrointestinal stromal tumor presenting as a pelvic mass.Gynecol Oncol,2003,91:630-635.
3Krokowski M, Jocham D, Choi H, et al. Malignant extragastrointestinal stromal tumor of bladder.J Urol,2003,169:1790-1791.
4Emory TS, Sobin LH, Lukes L, et al. Prognosis of gastrointestinal smooth-muscle (stromal) tumors: dependence on anatomic site.Am J Surg Pathol,1999,23:82-87.
5Dematteo RP, Heinrich MC, El-Rifai WM, et al. Clinical management of gastrointestinal stromal tumors: before and after STI-571.Hum Pathol,2002,33:466-477.
6Verweij J, van Oosterom A, Blay JY, et al. Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study.Eur J Cancer,2003,39:2006-2011.
